{"parse":{"title":"Zelen's design","pageid":5352357,"revid":822625380,"text":{"*":"<div class=\"mw-parser-output\"><p><b>Zelen's design</b> is an <a href=\"/wiki/Experimental_design\" class=\"mw-redirect\" title=\"Experimental design\">experimental design</a> for <a href=\"/wiki/Randomized_clinical_trials\" class=\"mw-redirect\" title=\"Randomized clinical trials\">randomized clinical trials</a> proposed by <a href=\"/wiki/Harvard_School_of_Public_Health\" class=\"mw-redirect\" title=\"Harvard School of Public Health\">Harvard School of Public Health</a> <a href=\"/wiki/Statistician\" title=\"Statistician\">statistician</a> <a href=\"/wiki/Marvin_Zelen_(biostatistician)\" class=\"mw-redirect\" title=\"Marvin Zelen (biostatistician)\">Marvin Zelen</a> (1927-2014). In this design, patients are randomized to either the treatment or <a href=\"/wiki/Scientific_control\" title=\"Scientific control\">control group</a> before giving <a href=\"/wiki/Informed_consent\" title=\"Informed consent\">informed consent</a>. Because the group to which a given patient is assigned is known, consent can be sought conditionally. \n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Overview\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Overview</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Statistical_and_epidemiological_issues\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Statistical and epidemiological issues</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#See_also\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#References\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#External_links\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Overview\">Overview</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Zelen%27s_design&amp;action=edit&amp;section=1\" title=\"Edit section: Overview\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>In this design, those patients receiving standard care need not be consented for participation in the study other than possibly for privacy issues. On the other hand, those patients randomized to the experimental group are consented as usual, except that they are consenting to the certainty of receiving the experimental treatment only; alternatively these patients can decline and receive the standard treatment instead. \n</p><p>In comparison, the current predominant design is for consent to be solicited prior to randomization. That is, eligible patients are asked if they would agree to participate in the clinical trial as a whole. This entails agreeing to receiving the experimental treatment as a possibility, receiving the control treatment as a possibility, and the uncertainty involved in not knowing.\n</p>\n<h2><span class=\"mw-headline\" id=\"Statistical_and_epidemiological_issues\">Statistical and epidemiological issues</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Zelen%27s_design&amp;action=edit&amp;section=2\" title=\"Edit section: Statistical and epidemiological issues\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>There are a number of advantages conferred by the post-randomization consent design. \n</p>\n<ul><li>Clinicians are more comfortable with this design because each time consent is only sought for one treatment without the uncertainty of randomization.</li>\n<li>Patients correspondingly are not subjected to the uncomfortable feeling that they may or may not be receiving the experimental treatment. This means effects such as <a href=\"/wiki/Resentful_demoralization\" title=\"Resentful demoralization\">resentful demoralization</a> will not become an issue. Analogously, since patients allocated to the standard care group are not necessarily aware of the existence of an alternative treatment, <a href=\"/wiki/Hawthorne_effect\" title=\"Hawthorne effect\">Hawthorne effect</a> is also less of an issue.</li></ul>\n<p>Some disadvantages include:\n</p>\n<ul><li>Contamination by crossing over may be more likely since patients assigned to the treatment group are fully aware of their assignment. Notably, statistical analysis should be performed with intention-to-treat.</li>\n<li>Lack of allocation concealment, which may produce further bias.</li>\n<li>Ethical drawbacks. Palmer (2002) notes, \"in the few trials where [Zelen randomization] was employed it has been met with disapproval from participants and others, being deemed inappropriately deceptive and manipulative, at least in trials for serious or life-threatening conditions.\"</li></ul>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Zelen%27s_design&amp;action=edit&amp;section=3\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Cluster_randomised_controlled_trial\" title=\"Cluster randomised controlled trial\">Cluster randomised controlled trial</a></li>\n<li><a href=\"/wiki/Marvin_Zelen_(biostatistician)\" class=\"mw-redirect\" title=\"Marvin Zelen (biostatistician)\">Marvin Zelen (biostatistician)</a></li>\n<li><a href=\"/wiki/Randomized_controlled_trial\" title=\"Randomized controlled trial\">Randomized controlled trial</a></li>\n<li><a href=\"/wiki/Statistics\" title=\"Statistics\">Statistics</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Zelen%27s_design&amp;action=edit&amp;section=4\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><cite class=\"citation journal\">Zelen, Marvin (1979). \"A New Design for Randomized Clinical Trials\". <i><a href=\"/wiki/The_New_England_Journal_of_Medicine\" title=\"The New England Journal of Medicine\">The New England Journal of Medicine</a></i>. <b>300</b>: 1242\u20131245. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJM197905313002203\">10.1056/NEJM197905313002203</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/431682\">431682</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+England+Journal+of+Medicine&amp;rft.atitle=A+New+Design+for+Randomized+Clinical+Trials&amp;rft.volume=300&amp;rft.pages=1242-1245&amp;rft.date=1979&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM197905313002203&amp;rft_id=info%3Apmid%2F431682&amp;rft.aulast=Zelen&amp;rft.aufirst=Marvin&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AZelen%27s+design\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li>\n<li><cite class=\"citation journal\">Torgerson, D. J.; Roland, M. (1998). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC1112637\">\"What is Zelen's design?\"</a>. <i>BMJ</i>. <b>316</b> (7131): 606. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1136/bmj.316.7131.606\">10.1136/bmj.316.7131.606</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC1112637\">1112637</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/9518917\">9518917</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BMJ&amp;rft.atitle=What+is+Zelen%27s+design%3F&amp;rft.volume=316&amp;rft.issue=7131&amp;rft.pages=606&amp;rft.date=1998&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1112637&amp;rft_id=info%3Apmid%2F9518917&amp;rft_id=info%3Adoi%2F10.1136%2Fbmj.316.7131.606&amp;rft.aulast=Torgerson&amp;rft.aufirst=D.+J.&amp;rft.au=Roland%2C+M.&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1112637&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AZelen%27s+design\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li>\n<li><cite class=\"citation journal\">Palmer, C. R. (2002). \"Ethics, data-dependent designs, and the strategy of clinical trials: time to start learning-as-we-go?\". <i>Statistical Methods in Medical Research</i>. <b>11</b> (5): 381\u2013402. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1191/0962280202sm298ra\">10.1191/0962280202sm298ra</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0962-2802\">0962-2802</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/12357585\">12357585</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Statistical+Methods+in+Medical+Research&amp;rft.atitle=Ethics%2C+data-dependent+designs%2C+and+the+strategy+of+clinical+trials%3A+time+to+start+learning-as-we-go%3F&amp;rft.volume=11&amp;rft.issue=5&amp;rft.pages=381-402&amp;rft.date=2002&amp;rft.issn=0962-2802&amp;rft_id=info%3Apmid%2F12357585&amp;rft_id=info%3Adoi%2F10.1191%2F0962280202sm298ra&amp;rft.aulast=Palmer&amp;rft.aufirst=C.+R.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AZelen%27s+design\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li></ul>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Zelen%27s_design&amp;action=edit&amp;section=5\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.springerlink.com.ezp-prod1.hul.harvard.edu/content/v78321530508077m/?p=95da6589690a45b0843f86aa63f4df37&amp;pi=1\">Introduction to the Special Issue Dedicated to Marvin Zelen </a>, Lifetime Data Analysis, Issue Volume 10, Number 4 / December, 2004. DOI 10.1007/s10985-004-4769-7, Pages 321-323.</li></ul>\n\n<!-- \nNewPP limit report\nParsed by mw1330\nCached time: 20180908033714\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.080 seconds\nReal time usage: 0.097 seconds\nPreprocessor visited node count: 128/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 6196/2097152 bytes\nTemplate argument size: 0/2097152 bytes\nHighest expansion depth: 2/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 0/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.038/10.000 seconds\nLua memory usage: 1.73 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%   74.482      1 -total\n 99.71%   74.268      3 Template:Cite_journal\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:5352357-0!canonical and timestamp 20180908033714 and revision id 822625380\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","*":"Design_of_experiments"},{"sortkey":"","*":"Clinical_research"}],"links":[{"ns":0,"exists":"","*":"Cluster randomised controlled trial"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Experimental design"},{"ns":0,"exists":"","*":"Harvard School of Public Health"},{"ns":0,"exists":"","*":"Hawthorne effect"},{"ns":0,"exists":"","*":"Informed consent"},{"ns":0,"exists":"","*":"International Standard Serial Number"},{"ns":0,"exists":"","*":"Marvin Zelen (biostatistician)"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Randomized clinical trials"},{"ns":0,"exists":"","*":"Randomized controlled trial"},{"ns":0,"exists":"","*":"Resentful demoralization"},{"ns":0,"exists":"","*":"Scientific control"},{"ns":0,"exists":"","*":"Statistician"},{"ns":0,"exists":"","*":"Statistics"},{"ns":0,"exists":"","*":"The New England Journal of Medicine"}],"templates":[{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"}],"images":["Lock-green.svg"],"externallinks":["//doi.org/10.1056/NEJM197905313002203","//www.ncbi.nlm.nih.gov/pubmed/431682","//www.ncbi.nlm.nih.gov/pmc/articles/PMC1112637","//doi.org/10.1136/bmj.316.7131.606","//www.ncbi.nlm.nih.gov/pubmed/9518917","//doi.org/10.1191/0962280202sm298ra","//www.worldcat.org/issn/0962-2802","//www.ncbi.nlm.nih.gov/pubmed/12357585","http://www.springerlink.com.ezp-prod1.hul.harvard.edu/content/v78321530508077m/?p=95da6589690a45b0843f86aa63f4df37&pi=1"],"sections":[{"toclevel":1,"level":"2","line":"Overview","number":"1","index":"1","fromtitle":"Zelen's_design","byteoffset":456,"anchor":"Overview"},{"toclevel":1,"level":"2","line":"Statistical and epidemiological issues","number":"2","index":"2","fromtitle":"Zelen's_design","byteoffset":1277,"anchor":"Statistical_and_epidemiological_issues"},{"toclevel":1,"level":"2","line":"See also","number":"3","index":"3","fromtitle":"Zelen's_design","byteoffset":2554,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"4","index":"4","fromtitle":"Zelen's_design","byteoffset":2698,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"5","index":"5","fromtitle":"Zelen's_design","byteoffset":3531,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"Zelen's design","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q8068723"}]}}